Training and drug development: what patient access still needs
The October 23 briefing reviews two reports published on October 22. It separates professional collaboration and drug-development plans from access to treatment.
Three things to know
A report from Chongqing describes a 27-day respiratory intervention course that began on October 15 with 15 healthcare professionals. Training and procedure observation do not establish patient referrals.
BioSpace interviewed a Merck executive about sac-TMT, a TROP2-targeted antibody-drug conjugate developed with Kelun-Biotech. The discussion of its design is a company view, not independent proof of clinical advantage.
At the briefing’s cutoff, three Phase 3 presentations were planned for ESMO. Detailed congress results were still pending. The reports do not demonstrate new treatment access for overseas patients.
This is a dated video briefing. Reports and availability may have changed since it was recorded; confirm current details before making plans.